Adenomesenteritis following SARS-CoV-2 Vaccination in Children: A Case Report and Review of The Literature

At present, the vaccine authorized in children aged 5 years and older is the BNT162b2 messenger RNA COVID-19 vaccine. Unlike adults, there is limited data available in the pediatric age describing adverse events after vaccine. We report a case of adenomesenteritis in a young girl following the first...

Descripción completa

Detalles Bibliográficos
Autores principales: Bloise, Silvia, Marcellino, Alessia, Martucci, Vanessa, Sanseviero, Mariateresa, Testa, Alessia, Del Giudice, Emanuela, Spatuzzo, Mattia, Sermoneta, Daniel, Ventriglia, Flavia, Lubrano, Riccardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9321070/
https://www.ncbi.nlm.nih.gov/pubmed/35883977
http://dx.doi.org/10.3390/children9070993
Descripción
Sumario:At present, the vaccine authorized in children aged 5 years and older is the BNT162b2 messenger RNA COVID-19 vaccine. Unlike adults, there is limited data available in the pediatric age describing adverse events after vaccine. We report a case of adenomesenteritis in a young girl following the first dose of vaccine.

Ejemplares similares